drugset / Trial / NCT04048278

Lidocaine Infusion in Pancreatic Cancer

NCT04048278

Phase 0 Recruiting 46 enrolled University of Illinois at Chicago
RandomizedParallel-groupDouble-blindTreatment

Summary

This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.

Timeline

Start
2018-11-08
Primary completion
2027-11-08
Completion
2028-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 1 mg/kg Intravenous
Subject Lidocaine Other / unclassified 1.5 mg/kg Intravenous